Approved incretin labels include special-population guidance, but retatrutide does not yet have approved labeling to guide routine clinical decisions [2], [12], [13]
In conclusion, your mileage with DSIP may vary
Discontinuation rates due to adverse events in TRIUMPH-3 were 9.8% (9 mg) and 13.5% (12 mg) with retatrutide, compared with 4.8% for placebo
Impact of the unstirred water layer on the permeation of small-molecule drugs
Although no clinical studies have directly compared gastric emptying with long- and short-acting GLP-1RAs, their relative effects were illustrated in an animal study comparing liraglutide and exenatide, where the latter was shown to have a profound effect on gastric emptying while liraglutide had very little effect (124, 189)
Increasing redness, spreading warmth, or swelling that develops hours later is not